PIPELINE GROWTH Agomab is a Clinical-stage biopharmaceutical focused on fibro-inflammation with Phase 2b design underway for Ontunisertib in Fibrostenosing Crohn's Disease and a Phase 2 study planned for IPF with AGMB-447, signaling active late-stage development and potential near-term collaboration or licensing opportunities.

REGULATORY ALIGNMENT Regulatory progress including FDA alignment on NOV-ERA Phase 2b design and novel endpoints suggests opportunities for strategic partnerships with CROs, advisory firms, or pharma companies seeking to co-develop fibrosis-focused assets under clear regulatory pathways.

FISCAL HEALTH Recent IPO funding and strengthened cash runway into 2029, plus 2025 financials showing growing investor confidence, indicate capacity for co-development deals, milestone-driven collaborations, and upfront funding discussions with larger biopharma interested in fibrosis therapies.

BIG MARKET ACCESS Programs targeting high-need indications such as Crohn's disease with FSCD and IPF address large patient populations and unmet medical need, making them attractive for strategic partnerships, co-promotion arrangements, and access-focused distribution deals.

CONFERENCE VISIBILITY Active participation in industry conferences and strong management engagement signals readiness for partner pitches, due diligence, and accelerated business development conversations around platform collaborations and asset acquisitions.